Cencora price target raised to $301 from $287 at Leerink

Leerink analyst Michael Cherny raised the firm’s price target on Cencora (COR) to $301 from $287 and keeps an Outperform rating on the shares after the company “continued its beat-and-raise streak” with “very strong” Q1 results and a second FY25 guidance increase in the last month. The increase in core guidance for U.S. Healthcare EBIT was almost 4%, the firm estimates, despite this just being the first fiscal quarter, which “exemplifies” both a healthy end market and Cencora’s ability to generate outsized growth, the analyst tells investors.